| Date | Time | Source | |
| 05/09/2013 | 3:00PM | PRNUS | Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference
Neurocrine Biosciences To Present At The Bank of America Merrill Lynch 2013 Health Care Conference Live Audio Webcast Thursday, May 16, 2013 PR Newswire SAN DIEGO, May 9, 2013 SAN DIEGO, May 9, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>> |
| 05/02/2013 | 4:02PM | PRNUS | Neurocrine Biosciences Reports First Quarter 2013 Results
Neurocrine Biosciences Reports First Quarter 2013 Results ELAGOLIX ENTERS PHASE IIB FOR UTERINE FIBROIDS, ENDOMETRIOSIS PHASE III PROGRAM ON TRACK PR Newswire SAN DIEGO, May 2, 2013 SAN DIEGO, May 2, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended... More...>> |
| 04/26/2013 | 1:00PM | PRNUS | Neurocrine Biosciences Announces Conference Call And Webcast To Present First Quarter 2013 Financial Results
Neurocrine Biosciences Announces Conference Call And Webcast To Present First Quarter 2013 Financial Results Conference Call and Webcast Scheduled For Thursday, May 2, 2013 PR Newswire SAN DIEGO, April 26, 2013 SAN DIEGO, April 26, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that the... More...>> |
| 04/24/2013 | 1:00PM | PRNUS | Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference
Neurocrine Biosciences to Present at the Needham 12th Annual Healthcare Conference Live Audio Webcast Wednesday, May 1, 2013 PR Newswire SAN DIEGO, April 24, 2013 SAN DIEGO, April 24, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive Officer... More...>> |
| 03/27/2013 | 7:00AM | PRNUS | Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids
Neurocrine Biosciences Announces the Start of Phase IIb Study of Elagolix in Uterine Fibroids STUDY WILL EVALUATE SIX MONTHS OF TREATMENT IN 280 SUBJECTS PR Newswire SAN DIEGO, March 27, 2013 SAN DIEGO, March 27, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that a Phase IIb clinical... More...>> |
| 03/11/2013 | 11:00AM | PRNUS | Neurocrine Biosciences To Present At The 25th Annual Roth Conference
Neurocrine Biosciences To Present At The 25th Annual Roth Conference Live Audio Webcast Monday, March 18, 2013 PR Newswire SAN DIEGO, March 11, 2013 SAN DIEGO, March 11, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of Neurocrine Biosciences... More...>> |
| 02/27/2013 | 11:00AM | PRNUS | Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference
Neurocrine Biosciences To Present At The Cowen And Company 33rd Annual Health Care Conference Live Audio Webcast Wednesday, March 6, 2013 PR Newswire SAN DIEGO, Feb. 27, 2013 SAN DIEGO, Feb. 27, 2013 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Tim Coughlin, Chief Financial Officer of... More...>> |
| 02/08/2013 | 7:00AM | PRNUS | Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results
Neurocrine Biosciences Reports Fourth Quarter And Year End 2012 Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial"; color:black;... More...>> |
| 02/06/2013 | 11:00AM | PRNUS | Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013
Neurocrine Biosciences To Present At The Leerink Swann Global Healthcare Conference 2013 /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em; font-family:"Arial";... More...>> |
| 02/01/2013 | 3:33PM | PRNUS | Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results
Neurocrine Biosciences Announces Conference Call And Webcast To Present Fourth Quarter And Year-End 2012 Financial Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p... More...>> |
| 01/23/2013 | 4:05PM | PRNUS | Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor
Neurocrine Biosciences Announces Additional European And United States Patents Issued On Proprietary VMAT2 Inhibitor /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:0.62em;... More...>> |
| 12/18/2012 | 4:12PM | PRNUS | Neurocrine Announces Start Of Second Phase IIb Study Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
Neurocrine Announces Start Of Second Phase IIb Study Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:8pt;... More...>> |
| 11/27/2012 | 5:00PM | PRNUS | Neurocrine Biosciences To Present At Deutsche Bank's 2012 dbAccess BioFEST
Neurocrine Biosciences To Present At Deutsche Bank's 2012 dbAccess BioFEST /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:8pt; font-family:"Arial"; color:black;... More...>> |
| 11/20/2012 | 5:00PM | PRNUS | Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference
Neurocrine Biosciences To Present At The 24th Annual Piper Jaffray Healthcare Conference /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:8pt; font-family:"Arial";... More...>> |
| 11/06/2012 | 1:00PM | PRNUS | Neurocrine Biosciences To Present At Lazard Capitalmarket's 9th Annual Healthcare Conference
Neurocrine Biosciences To Present At Lazard Capitalmarket's 9th Annual Healthcare Conference /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:8pt; font-family:"Arial";... More...>> |
| 10/31/2012 | 4:02PM | PRNUS | Neurocrine Biosciences Reports Third Quarter 2012 Results
Neurocrine Biosciences Reports Third Quarter 2012 Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:8pt; font-family:"Arial"; color:black; } Neurocrine... More...>> |
| 10/24/2012 | 5:52PM | PRNUS | Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast to Present Third Quarter 2012 Financial Results /* Style Definitions */ span.prnews_span { font-size:8pt; font-family:"Arial"; color:black; } a.prnews_a { color:blue; } li.prnews_li { font-size:8pt; font-family:"Arial"; color:black; } p.prnews_p { font-size:8pt;... More...>> |
| 10/01/2012 | 4:05PM | PRNUS | Neurocrine Announces Start Of Phase IIb Study Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia
Neurocrine Announces Start Of Phase IIb Study Of VMAT2 Inhibitor NBI-98854 For Treatment Of Tardive Dyskinesia Kinect Study to Evaluate Twelve Weeks of Continuous Dosing PR Newswire SAN DIEGO, Oct. 1, 2012 SAN DIEGO, Oct. 1, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has initiated... More...>> |
| 09/05/2012 | 5:18PM | PRNUS | Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference
Neurocrine Biosciences To Present At The Morgan Stanley Global Healthcare Conference Live Audio Webcast Wednesday, September 12, 2012 PR Newswire SAN DIEGO, Sept. 5, 2012 SAN DIEGO, Sept. 5, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that Kevin Gorman, President and Chief Executive... More...>> |
| 07/31/2012 | 4:05PM | PRNUS | Neurocrine Biosciences Reports Second Quarter 2012 Results
Neurocrine Biosciences Reports Second Quarter 2012 Results ELAGOLIX ENTERS PHASE III, VMAT2 PHASE IIB STUDY STARTS IN THIRD QUARTER PR Newswire SAN DIEGO, July 31, 2012 SAN DIEGO, July 31, 2012 /PRNewswire/ -- Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced its financial results for the quarter ended June 30... More...>> |
